Brad Margus

Mr. Margus currently serves as Co-Founder and Chief Executive Officer of Cerevance, a drug discovery company focused on brain diseases with sites in Massachusetts and the United Kingdom. From 2009-2012, as Chief Executive Officer of Envoy Therapeutics, he raised $8 million from investors, employed a unique technology to discover new compounds for brain diseases, and sold the company within three years for $140 million. From 2000 to 2007, Mr. Margus was the Chief Executive Officer of Perlegen Sciences, a leader in analyzing genetic variation that raised $257 million from investors, exceeded $100 million in revenues, and identified diagnostic markers for disease risk and drug response.

Mr. Margus has been a member of numerous government advisory committees as well as corporate and nonprofit boards. He currently serves on the Boards of Second Genome, Presage Biosciences and the non-profit A-T Children’s Project. Additionally, he serves as the Chair of the Network for Excellence in Neuroscience Clinical Trials External Oversight Board at the NIH.

Mr. Margus obtained his M.B.A. from Harvard Business School.